The specific objective of this application is to continue to provide patients in our region access to the National Cancer Institute treatment and cancer prevention/control research protocols through the Community Cancer Oncology Program (CCOP). A primary goal of the Sioux Community Cancer Consortium (SCCC) is to achieve 150 cancer treatment credits and 90 new cancer control credits per year. We will also achieve 75 follow up credits in the cancer control category per year. [Total credits/year = 150 treatment, 165 cancer control.] These are realistic numbers based on the past accomplishments of the SCCC. The SCCC is a two component;two affiliate community based clinical cancer research organization. The two major components are Sanford Oncology in Sioux Falls, SD and Siouxland Hematology -Oncology Associates in Sioux City, Iowa. There two components are a mere 90 miles apart on Interstate 29 in the rural Midwest. The Sanford component has two affiliate sites - Avera Cancer Institute (Avera Medical Oncology/Hematology and Avera Hematology and Transplant) Sioux Falls, SD and Front Range Cancer Specialists in Fort Collins, Colorado. The Sioux City, Iowa, component has a number of outreach sites. The geographic catchment area for the SCCC covers approximately 105,000 square miles in SE South Dakota, SW Minnesota, NW Iowa and NE Nebraska. The Fort Collins catchment area covers approximately 35,000 square miles. The SCCC primary research base is the North Central Cancer Treatment Group (NCCTG). The SCCC is a secondary CCOP of the Eastern Cooperative Oncology Group (ECOG). The SCCC is a member of the National Surgical Adjuvant Breast and Bowel Project (NSABP). We participated in the NSABP initial Breast Cancer Prevention Trial (BCPT), as well as in the STAR trial. We participated in the initial SWOG Protstate Cancer Prevention Trial (PCPT) as well as in the SELECT trial. We continue to follow all these prevention participants. We participate in CTSU studies. The SCCC research team is dedicated to excellence in protocol administration and data management. The SCCC consists of 23 core investigators in medical . oncology, radiation oncology, and surgery. There are a number of supporting physicians in other medical disciplines.
The Sioux Community Cancer Consortium(SCCC)- CCOP project provides access to NCI cancer treatment and cancer prevention/control trials for patients in our region. The SCCC provides education and resources for physicians in our region regarding clinical cancer treatment trials and cancer prevention/control trials. The SCCC will continue to address the participation of women and minorities in NCI cancer trials.
|Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650|
|Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703|
|Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662|
|Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85|
|Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068|
|Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671|
|Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:|
|Schneider, Bryan P; O'Neill, Anne; Shen, Fei et al. (2015) Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer 113:1651-7|
|Liu, Heshan; Tan, Angelina D; Qin, Rui et al. (2015) Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag 2:|
|Wagner-Johnston, Nina D; Sloan, Jeff A; Liu, Heshan et al. (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-43|
Showing the most recent 10 out of 72 publications